Somaxon Pharmaceuticals, Inc. operates in the Pharmaceutical preparations sector. Somaxon Pharmaceuticals, Inc. (Somaxon) is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of branded products and late-stage product candidates. In March 2010, the United States Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Silenor three milligram and six milligram tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. Silenor was made commercially available by prescription in the United States in September 2010. The Company's focus is on commercial activities relating to Silenor. As of December 31, 2010, the clinical development program for Silenor included four Phase 3 clinical trials. In September 2010, the Company acquired the worldwide license from ProCom One, Inc. (ProCom) to certain patents to develop and commercialize low dosages of doxepin for the treatment of insomnia. In our complete report available for purchase the company is compared to: Incoming, Incorporation, Eat At Joes Limited and Axion International Holdings, Incorporation.